Celastrol, a natural plant compound, reduces fatty liver disease by targeting a protein called CD36 in specialized liver cells, preventing excessive fat absorption and inflammation. According to Gram Research analysis, the compound works by reducing USP12, a protein that normally stabilizes CD36, allowing it to be broken down. This mechanism was confirmed in both mouse models and human liver tissue samples from patients with steatohepatitis, suggesting a promising new treatment approach for fatty liver disease independent of weight loss.
Scientists discovered how a natural compound called celastrol helps treat fatty liver disease by targeting specific cells in the liver. According to Gram Research analysis, the compound works by stopping liver cells from absorbing too much fat and triggering inflammation. The research identifies a protein called CD36 in special liver cells as the key player in both fat storage and immune responses. This finding could lead to new treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition that affects millions of people worldwide, even those who aren’t overweight.
Key Statistics
A 2026 research study found that celastrol reduces liver inflammation and fat accumulation in mice with diet-induced fatty liver disease by targeting the USP12/CD36 axis in sinusoidal endothelial cells.
Human liver tissue analysis from patients with steatohepatitis showed concurrent upregulation of both USP12 and CD36 proteins, confirming the clinical relevance of the therapeutic pathway identified in animal models.
The research demonstrates that CD36 in liver sinusoidal endothelial cells acts as a master control point coordinating both hepatic lipid transport and inflammatory immune responses in fatty liver disease.
The Quick Take
- What they studied: How a natural plant compound called celastrol treats fatty liver disease and what molecular mechanisms make it work
- Who participated: Laboratory studies using mice with diet-induced fatty liver disease, plus analysis of human liver tissue samples from patients with steatohepatitis
- Key finding: Celastrol reduces liver fat and inflammation by targeting a protein called CD36 in specialized liver cells, preventing excessive fat uptake and immune cell recruitment
- What it means for you: This research identifies a new therapeutic target for treating fatty liver disease without requiring weight loss, though human clinical trials are still needed to confirm safety and effectiveness
The Research Details
Researchers used mice fed a special high-fat diet designed to cause fatty liver disease similar to the human condition. They then treated some mice with celastrol, a compound derived from a plant used in traditional medicine, and compared their liver health to untreated mice. The scientists used advanced molecular techniques to trace exactly how celastrol works inside liver cells, identifying the specific proteins involved in the process.
They discovered that celastrol targets a protein called USP12, which normally protects another protein called CD36. CD36 sits on the surface of specialized liver cells called sinusoidal endothelial cells (LSECs), which act as gatekeepers controlling what enters and exits the liver. By reducing USP12, celastrol allows CD36 to be broken down, which then reduces fat uptake and inflammation.
To confirm their findings were relevant to humans, the researchers examined liver tissue from patients with steatohepatitis and found that both USP12 and CD36 were abnormally high, supporting the importance of this pathway in human disease.
This research approach is important because it identifies not just that celastrol works, but exactly how it works at the molecular level. Understanding the specific mechanism allows scientists to develop more targeted treatments and potentially create synthetic drugs that work even better than the natural compound. Additionally, the study focuses on a liver cell type (LSECs) that hasn’t been thoroughly studied before, revealing these cells play a central role in controlling both fat metabolism and immune responses.
The study demonstrates strong scientific rigor by using multiple complementary approaches: animal models, molecular analysis, and human tissue validation. The findings in human liver samples support the relevance of the mouse model results. However, the research is primarily laboratory-based, and human clinical trials are needed to confirm that celastrol is safe and effective in patients. The specific sample sizes for human tissue analysis were not detailed in the abstract.
What the Results Show
Celastrol successfully reduced liver inflammation and fat accumulation in mice with diet-induced fatty liver disease. The compound worked by decreasing levels of a protein called USP12, which normally stabilizes CD36 on liver cell surfaces. When USP12 decreased, CD36 was broken down and removed from cells, which reduced the amount of fat these cells could absorb.
This reduction in CD36 had two major effects: it decreased the transport of harmful lipids into the liver, and it reduced the recruitment of immune cells (macrophages) that cause inflammation. The researchers found that CD36 in sinusoidal endothelial cells acts as a master control point for both fat metabolism and immune responses in the liver.
When the team examined liver tissue from patients with steatohepatitis, they found that both USP12 and CD36 were significantly elevated compared to healthy livers, suggesting this same pathway is disrupted in human disease. This human tissue evidence strongly supports that the findings from mouse studies are relevant to understanding and treating the human condition.
The research revealed that sinusoidal endothelial cells (LSECs) are more important for controlling liver metabolism and inflammation than previously recognized. These specialized cells, which line the liver’s blood vessels, act as sophisticated gatekeepers that coordinate multiple aspects of liver health. The study also demonstrated that the USP12/CD36 axis represents a previously unidentified therapeutic target, opening new possibilities for drug development beyond celastrol.
Previous research showed that celastrol helps prevent obesity-related fatty liver disease, but this study is the first to demonstrate that it directly treats liver inflammation and fat accumulation through a specific molecular mechanism. The identification of CD36 in liver endothelial cells as a central regulator expands our understanding beyond previous work focusing on CD36 in other cell types. This research also highlights the importance of liver cell heterogeneity—different liver cells play distinct roles—which represents an emerging area in liver disease research.
The primary limitation is that this research was conducted mainly in laboratory mice, not humans. While the human tissue analysis supports the relevance of findings, actual clinical trials in patients are needed to confirm safety and effectiveness. The study does not specify the exact number of human liver samples analyzed or provide detailed patient demographics. Additionally, the research focuses on one specific pathway; other mechanisms contributing to fatty liver disease may exist. Long-term effects of celastrol treatment were not evaluated, and optimal dosing for human use has not been determined.
The Bottom Line
Based on this research, celastrol represents a promising therapeutic candidate for fatty liver disease that works through a newly identified mechanism. However, it is too early to recommend celastrol as a treatment outside of clinical trials. People with fatty liver disease should continue following established recommendations: maintaining a healthy diet, regular exercise, limiting alcohol, and working with their healthcare provider. Future clinical trials will determine whether celastrol or drugs targeting the USP12/CD36 pathway can become standard treatments.
This research is most relevant to people with metabolic dysfunction-associated steatohepatitis (MASH), particularly those who cannot lose weight through diet and exercise alone. It’s also important for people with fatty liver disease who are not overweight, as this research shows treatment benefits independent of obesity. Healthcare providers specializing in liver disease and pharmaceutical researchers developing new treatments should pay close attention to these findings. People without liver disease do not need to take action based on this research at this time.
In the mouse studies, celastrol showed effects relatively quickly, but the timeline for human benefit cannot be determined from this research. If celastrol or similar drugs enter clinical trials, it typically takes 3-7 years to complete Phase 1, 2, and 3 trials before potential FDA approval. Even if approved, benefits in individual patients would depend on disease severity, adherence to treatment, and other personal factors. Realistic expectations are that new treatments based on this research might become available within 5-10 years.
Frequently Asked Questions
What is celastrol and where does it come from?
Celastrol is a natural compound derived from plants traditionally used in Asian medicine. The 2026 research shows it reduces liver fat and inflammation by targeting specific proteins involved in fatty liver disease, though human clinical trials are still needed to confirm its safety and effectiveness as a treatment.
Can celastrol treat fatty liver disease without weight loss?
The research suggests celastrol may help treat fatty liver disease independently of weight changes by reducing fat absorption and inflammation in liver cells. However, this finding comes from laboratory studies in mice and human tissue samples. Clinical trials in patients are necessary to confirm whether weight loss is still beneficial alongside celastrol treatment.
How does celastrol work to reduce liver fat?
Celastrol reduces a protein called USP12, which normally protects CD36 on liver cell surfaces. When USP12 decreases, CD36 is broken down, reducing the liver’s ability to absorb excess fat and preventing immune cells from causing inflammation. This dual action addresses both fat accumulation and liver inflammation.
Is celastrol available as a treatment for fatty liver disease now?
No, celastrol is not yet approved as a fatty liver disease treatment. This 2026 research identifies it as a promising candidate, but clinical trials in humans are required before it can become a standard medical treatment. Patients should continue working with their healthcare providers on established approaches like diet and exercise.
Who should consider this research if they have fatty liver disease?
People with metabolic dysfunction-associated steatohepatitis (MASH), especially those who cannot lose weight through diet and exercise, should be aware of this research. Those with fatty liver disease who are not overweight may find this particularly relevant, as it shows treatment benefits independent of obesity. Discuss these findings with your healthcare provider.
Want to Apply This Research?
- Track liver health markers monthly: record any available liver enzyme test results (ALT, AST), abdominal ultrasound findings, and symptoms like fatigue or abdominal discomfort. Note dietary fat intake and exercise minutes to correlate with liver health changes.
- Implement a liver-supporting diet by reducing saturated fat intake and increasing fiber-rich foods. Log daily meals and exercise in the app to monitor adherence. Set reminders for regular medical check-ups to monitor liver enzyme levels and disease progression.
- Establish a quarterly review cycle comparing liver enzyme trends, weight changes, and symptom severity. Use the app to track medication adherence if celastrol or related compounds become available through clinical trials. Create alerts for abnormal test results and schedule regular provider consultations.
This research is laboratory-based and has not yet been tested in human clinical trials. Celastrol is not currently approved by the FDA for treating fatty liver disease. People with fatty liver disease should not self-treat with celastrol or other supplements without consulting their healthcare provider. This article is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any new treatment or supplement, especially if you have liver disease or take other medications.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.